Stay updated with breaking news from Stork Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
San Diego-based Shoreline Biosciences, a developer of cell immunotherapies for treating solid tumors and hematologic malignancies, has raised $140M in a financing round, the company said today. The fu
Gilead Sciences and BeiGene, which started research alliances with Shoreline Biosciences earlier this year, are among the investors in the biotech's latest financing. The preclinical-stage company technology develops cell therapies for cancer by using natural killer cells.
ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs small molecules intended to do the work of biologic and peptide drugs.
Published: May 03, 2021 SAN DIEGO, May 3, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of Vanessa L. Jacoby as Chief Financial Officer. Ms. Jacoby brings more than twenty years of experience as a financial leader to Shoreline, with a strong background in company building and financ...